OccuRx is a Melbourne, Victoria, Australia-based biopharmaceutical company launched to develop a new class of drugs to prevent the health burden associated with fibrosis. Led by Dr Darren Kelly, the company has established preclinical proof of concept with its lead anti-fibrotic compound in an animal model of ocular inflammation and fibrosis. OccuRx intends to use the funds to continue development of its compound. The company launched with up to AU$6.5M available in staged tranches of venture capital funding. Investment came from a consortium including the Medical Research Commercialisation Fund (MRCF), Brandon Capital Partners and Uniseed.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

May 2015